Novel therapeutic strategy for stroke in rats by bone marrow stromal cells and ex vivo HGF gene transfer with HSV-1 vector - PubMed (original) (raw)

. 2006 Sep;26(9):1176-88.

doi: 10.1038/sj.jcbfm.9600273. Epub 2006 Jan 18.

Naosuke Nonoguchi, Naokado Ikeda, Takuji Watanabe, Daisuke Furutama, Daisuke Miyazawa, Hiroshi Funakoshi, Yoshinaga Kajimoto, Toshikazu Nakamura, Mari Dezawa, Masa-Aki Shibata, Yoshinori Otsuki, Robert S Coffin, Wei-Dong Liu, Toshihiko Kuroiwa, Shin-Ichi Miyatake

Affiliations

• PMID: 16421510
• DOI: 10.1038/sj.jcbfm.9600273

Novel therapeutic strategy for stroke in rats by bone marrow stromal cells and ex vivo HGF gene transfer with HSV-1 vector

Ming-Zhu Zhao et al. J Cereb Blood Flow Metab. 2006 Sep.

Abstract

Occlusive cerebrovascular disease leads to brain ischemia that causes neurological deficits. Here we introduce a new strategy combining mesenchymal stromal cells (MSCs) and ex vivo hepatocyte growth factor (HGF) gene transferring with a multimutated herpes simplex virus type-1 vector in a rat transient middle cerebral artery occlusion (MCAO) model. Gene-transferred MSCs were intracerebrally transplanted into the rats' ischemic brains at 2 h (superacute) or 24 h (acute) after MCAO. Behavioral tests showed significant improvement of neurological deficits in the HGF-transferred MSCs (MSC-HGF)-treated group compared with the phosphate-buffered saline (PBS)-treated and MSCs-only-treated group. The significant difference of infarction areas on day 3 was detected only between the MSC-HGF group and the PBS group with the superacute treatment, but was detected among each group on day 14 with both transplantations. After the superacute transplantation, we detected abundant expression of HGF protein in the ischemic brain of the MSC-HGF group compared with others on day 1 after treatment, and it was maintained for at least 2 weeks. Furthermore, we determined that the increased expression of HGF was derived from the transferred HGF gene in gene-modified MSCs. The percentage of apoptosis-positive cells in the ischemic boundary zone (IBZ) was significantly decreased, while that of remaining neurons in the cortex of the IBZ was significantly increased in the MSC-HGF group compared with others. The present study shows that combined therapy is more therapeutically efficient than MSC cell therapy alone, and it may extend the therapeutic time window from superacute to acute phase.

PubMed Disclaimer

Similar articles

• Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat.
  Chen J, Li Y, Katakowski M, Chen X, Wang L, Lu D, Lu M, Gautam SC, Chopp M. Chen J, et al. J Neurosci Res. 2003 Sep 15;73(6):778-86. doi: 10.1002/jnr.10691. J Neurosci Res. 2003. PMID: 12949903
• Novel therapeutic strategy to treat brain ischemia: overexpression of hepatocyte growth factor gene reduced ischemic injury without cerebral edema in rat model.
  Shimamura M, Sato N, Oshima K, Aoki M, Kurinami H, Waguri S, Uchiyama Y, Ogihara T, Kaneda Y, Morishita R. Shimamura M, et al. Circulation. 2004 Jan 27;109(3):424-31. doi: 10.1161/01.CIR.0000109496.82683.49. Epub 2004 Jan 5. Circulation. 2004. PMID: 14707023
• Recent Progress in Therapeutic Strategies for Ischemic Stroke.
  Yamashita T, Abe K. Yamashita T, et al. Cell Transplant. 2016;25(5):893-8. doi: 10.3727/096368916X690548. Epub 2016 Jan 18. Cell Transplant. 2016. PMID: 26786838 Review.
• [Gene therapy for cerebral infarction (cerebral ischemia)].
  Ishida A, Kawakami H, Yasuzumi F, Morishita R. Ishida A, et al. No To Shinkei. 2002 Mar;54(3):213-9. No To Shinkei. 2002. PMID: 11968812 Review. Japanese.

Cited by

• iPSC-derived mesenchymal stem cells attenuate cerebral ischemia-reperfusion injury by inhibiting inflammatory signaling and oxidative stress.
  Arakawa M, Sakamoto Y, Miyagawa Y, Nito C, Takahashi S, Nitahara-Kasahara Y, Suda S, Yamazaki Y, Sakai M, Kimura K, Okada T. Arakawa M, et al. Mol Ther Methods Clin Dev. 2023 Jul 15;30:333-349. doi: 10.1016/j.omtm.2023.07.005. eCollection 2023 Sep 14. Mol Ther Methods Clin Dev. 2023. PMID: 37637385 Free PMC article.
• Gastrin producing syngeneic mesenchymal stem cells protect non-obese diabetic mice from type 1 diabetes.
  Gaudreau MC, Gudi RR, Li G, Johnson BM, Vasu C. Gaudreau MC, et al. Autoimmunity. 2022 Mar;55(2):95-108. doi: 10.1080/08916934.2021.2012165. Epub 2021 Dec 9. Autoimmunity. 2022. PMID: 34882054 Free PMC article.
• Progress in Mesenchymal Stem Cell Therapy for Ischemic Stroke.
  Guo Y, Peng Y, Zeng H, Chen G. Guo Y, et al. Stem Cells Int. 2021 Jun 15;2021:9923566. doi: 10.1155/2021/9923566. eCollection 2021. Stem Cells Int. 2021. PMID: 34221026 Free PMC article. Review.
• Mesenchymal Stem Cells as a Gene Delivery Tool: Promise, Problems, and Prospects.
  Attia N, Mashal M, Puras G, Pedraz JL. Attia N, et al. Pharmaceutics. 2021 Jun 7;13(6):843. doi: 10.3390/pharmaceutics13060843. Pharmaceutics. 2021. PMID: 34200425 Free PMC article. Review.
• The Beneficial Potential of Genetically Modified Stem Cells in the Treatment of Stroke: a Review.
  Salehi MS, Safari A, Pandamooz S, Jurek B, Hooshmandi E, Owjfard M, Bayat M, Zafarmand SS, Miyan JA, Borhani-Haghighi A. Salehi MS, et al. Stem Cell Rev Rep. 2022 Feb;18(2):412-440. doi: 10.1007/s12015-021-10175-1. Epub 2021 May 25. Stem Cell Rev Rep. 2022. PMID: 34033001 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information